Immunotherapy for Lung Cancer Patients with Bone Metastases
Author Information
Author(s): Huang Zhangheng, Tong Yuexin, Zhu Lujian, Yang Binbin, Chen Kai, Dai Peiling
Primary Institution: The First Affiliated Hospital of Wenzhou Medical University
Hypothesis
This study aimed to determine the efficacy of immunotherapy in lung adenocarcinoma patients with bone metastases.
Conclusion
Immunotherapy provides a significant survival advantage for lung adenocarcinoma patients with bone metastases.
Supporting Evidence
- Immunotherapy significantly improved overall survival in patients with lung adenocarcinoma and bone metastases.
- A predictive model was developed to identify patients who would benefit most from immunotherapy.
- Kaplan-Meier survival curves showed enhanced overall survival for patients receiving immunotherapy.
Takeaway
This study found that immunotherapy can help lung cancer patients with bone problems live longer and better.
Methodology
A multicenter retrospective analysis using Kaplan-Meier analysis, Log-rank test, and propensity score matching.
Potential Biases
Selection bias due to differences in baseline characteristics of patients receiving immunotherapy versus those who did not.
Limitations
Selection bias is inevitable due to the retrospective nature of the study and limited patient-related information.
Participant Demographics
The study included a diverse cohort with no significant differences in age, race, or sex between groups.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website